Skip to content Skip to footer

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Shots:Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine preventionBoth studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected…

Read more

Top 20 R&D Spending Biopharma Companies of 2025  

Shots: Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…

Read more

Know Your Investor: Venrock Healthcare Capital Partners (August’25 Edition)   

Shots:    Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences This edition spotlights Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies In 2024, Venrock Healthcare Capital Partners invested approximately $4.56B across six…

Read more

Top 20 immunology companies of 2025

Top 20 Immunology Companies of 2025

Shots: Immunology continues to be a key focus area, with biopharmaceutical companies rigorously advancing innovative therapies including drugs, vaccines, and antibodies to address evolving patient needs and improve disease outcomes In 2024, the global immunology market size was valued at $109.4B and expected to reach $254.23B by 2032, with a CAGR of 11.8% from 2024…

Read more

Top 20 Vaccines of 2025

Top 20 Vaccines of 2025 

Shots: Vaccines play a critical role in combating infectious diseases by stimulating antibody production and establishing immune memory. Biopharma companies around the globe continue to drive innovation in vaccine development, targeting both infectious and preventable diseases The global vaccine market was valued at $87.75B in 2024 and is projected to reach $151.96B by 2033, reflecting…

Read more

Know Your Investor: Invus (July’25 Edition)

Shots:     Welcome to the 2025 edition of Know Your Investor, highlighting leading venture capital firms shaping the future of healthcare innovation This edition highlights Invus, an investment firm focused on supporting life sciences companies committed to advancing breakthroughs that enhance public health In 2024, Invus invested around $4.15B across six funding rounds, expanding its portfolio…

Read more

20 Innovative Digital Therapeutics Companies of 2025

20 Innovative Digital Therapeutics Companies of 2025 

Shots:  The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029 PharmaShots presents a concise report…

Read more